We are live on
!
Find out more
Wealth Enhancement Advisory Services Portfolio holdings
AUM
$59.8B
1-Year Est. Return
29.42%
This Fund
S&P 500
This Quarter
Est. Return
+7.52%
1 Year Est. Return
+29.42%
3 Year Est. Return
+77.06%
5 Year Est. Return
+66.38%
10 Year Est. Return
+178.95%
AUM
$66.1B
AUM Growth
+$5.68B
(+9.4%)
Cap. Flow
+$2.35B
Cap. Flow
% of AUM
3.55%
Top 10 Holdings %
Top 10 Hldgs %
24.01%
Holding
3,725
New
349
Increased
1,942
Reduced
1,142
Closed
143
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Palantir
PLTR
|
+$179M |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
+$160M |
| 3 |
ALPS Smith Core Plus Bond ETF
SMTH
|
+$146M |
| 4 |
Home Depot
HD
|
+$85.7M |
| 5 |
Accenture
ACN
|
+$85.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$116M |
| 2 |
Cisco
CSCO
|
+$92.3M |
| 3 |
IBM
IBM
|
+$79.9M |
| 4 |
Janus Henderson AAA CLO ETF
JAAA
|
+$69.5M |
| 5 |
NextEra Energy
NEE
|
+$48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.45% |
| 2 | Financials | 6.35% |
| 3 | Industrials | 4.57% |
| 4 | Healthcare | 4% |
| 5 | Consumer Discretionary | 3.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MIN
3476
Aberdeen Intermediate Income Fund
MIN
$278M
| $30K | ﹤0.01% |
11,283
| – | – |
|
3477
Lexaria Bioscience
LEXX
$8.86M
| $29.9K | ﹤0.01% |
2,385
+333
| +16% | +$4.83K |
|
3478
Lexicon Pharmaceuticals
LXRX
$1.09B
| $28.7K | ﹤0.01% |
18,877
-55,577
| -75% | -$63.1K |
|
3479
Rafael Holdings
RFL
$99.3M
| $28.1K | ﹤0.01% |
21,474
+4,271
| +25% | +$7.18K |
|
3480
Ocugen
OCGN
$441M
| $27.7K | ﹤0.01% |
15,729
-1,354
| -8% | -$1.5K |
|
3481
Standard BioTools
LAB
$306M
| $27K | ﹤0.01% |
20,744
+388
| +2% | +$508 |
|
3482
MAIA Biotechnology
MAIA
$84.5M
| $26.5K | ﹤0.01% |
14,800
| – | – |
|
3483
Pacific Biosciences
PACB
$354M
| $24.8K | ﹤0.01% |
17,717
-12,396
| -41% | -$16.8K |
|
3484
Ampco-Pittsburgh
AP
$186M
| $23.9K | ﹤0.01% |
10,573
-581
| -5% | -$1.73K |
|
3485
BioLife Solutions
BLFS
$1.69B
| $23.9K | ﹤0.01% |
+908
| New | +$21.5K |
|
|
FRMM
3486
Forum Markets
FRMM
$83M
| $23.8K | ﹤0.01% |
+1,021
| New | +$30.6K |
|
3487
Innoviz Technologies
INVZ
$114M
| $23.7K | ﹤0.01% |
+10,109
| New | +$17.2K |
|
|
NUAI
3488
New Era Energy & Digital Inc
NUAI
$536M
| $22.8K | ﹤0.01% |
+13,641
| New | +$7.55K |
|
3489
CALL
BlackBerry
BB
$5.29B
| $22.6K | ﹤0.01% |
150,600
+80,600
| +115% | +$320K |
|
3490
BioCardia
BCDA
$14.2M
| $22.4K | ﹤0.01% |
+17,000
| New | +$33.2K |
|
3491
Humacyte
HUMA
$193M
| $22.4K | ﹤0.01% |
13,600
-7,986
| -37% | -$15.6K |
|
3492
Expensify
EXFY
$233M
| $21.9K | ﹤0.01% |
+12,907
| New | +$26.1K |
|
3493
Destination XL Group
DXLG
$33M
| $21.5K | ﹤0.01% |
18,242
-238
| -1% | -$312 |
|
3494
BRC Inc
BRCC
$218M
| $20.6K | ﹤0.01% |
+14,899
| New | +$23.8K |
|
3495
DocGo
DCGO
$57.5M
| $20.4K | ﹤0.01% |
16,060
+2,091
| +15% | +$3.17K |
|
|
OKYO
3496
OKYO Pharma
OKYO
$81.3M
| $20.3K | ﹤0.01% |
10,000
| – | – |
|
3497
Neumora Therapeutics
NMRA
$295M
| $19.4K | ﹤0.01% |
10,433
-19,387
| -65% | -$31.3K |
|
3498
Cognition Therapeutics
CGTX
$94.9M
| $19.3K | ﹤0.01% |
11,000
+1,000
| +10% | +$1.36K |
|
3499
SKYX Platforms
SKYX
$167M
| $18.5K | ﹤0.01% |
16,335
+389
| +2% | +$442 |
|
|
CRDL
3500
Cardiol Therapeutics
CRDL
$169M
| $17.8K | ﹤0.01% |
16,770
-70
| -0.4% | -$85 |
|
Similar funds
QCM
NAMI
Wealth Enhancement Advisory Services's Q3 2025 Portfolio in Review
As of Q3 2025, Wealth Enhancement Advisory Services held 3,725 positions worth $66.1B, up 9.4% from $60.5B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Wealth Enhancement Advisory Services deployed $2.35B of net new capital in Q3 2025, opening 349 new positions and adding to 1,942 existing holdings. Its largest new stake was PIMCO Mortgage-Backed Securities Active Exchange-Traded Fund: 1,561,056 shares worth $77.3M.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 13% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was JPMorgan Chase, an estimated $116M trimmed.
- Wealth Enhancement Advisory Services's largest Q3 2025 buy was PIMCO Mortgage-Backed Securities Active Exchange-Traded Fund: 1,561,056 shares worth $77.3M.
- Wealth Enhancement Advisory Services added most to Palantir in Q3 2025, an estimated $179M increase.
- Wealth Enhancement Advisory Services's biggest Q3 2025 reduction was JPMorgan Chase, cutting an estimated $116M.
- Wealth Enhancement Advisory Services fully exited TCW Core Plus Bond ETF in Q3 2025, selling an estimated $16M.
- Wealth Enhancement Advisory Services's ten largest holdings make up 24% of its $66.1B portfolio in Q3 2025.
- Wealth Enhancement Advisory Services opened 349 new positions and closed 143 in Q3 2025.
- Wealth Enhancement Advisory Services's portfolio value rose 9.4% quarter-over-quarter to $66.1B.
Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2025, filed 29 Oct 2025.